Immunic
IMUX
51 hedge funds and large institutions have $51.5M invested in Immunic in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.
165% more call options, than puts
Call options by funds: $344K | Put options by funds: $130K
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
5% less capital invested
Capital invested by funds: $54.5M → $51.5M (-$2.98M)
6% less funds holding
Funds holding: 54 → 51 (-3)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$14.3M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$555K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$444K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$323K |
| 5 |
D.E. Shaw & Co
New York
|
+$69.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.45M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$91.3K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$84K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$78K |
| 5 |
SG Americas Securities
New York
|
-$76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
VOYA Investment Management
Atlanta,
Georgia
| $71 | – | – | – |
|
|
ARTA
52
A.R.T. Advisors
New York
| – | -$84K | -34 | Closed |
|
|
53
SG Americas Securities
New York
| – | -$76K | -31 | Closed |
|
|
VKH
54
Virtu KCG Holdings
New York
| – | -$78K | -31 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$28K | -11 | Closed |
|
56
JP Morgan Chase
New York
| – | -$6K | -2 | Closed |
|
57
Walleye Trading
New York
| – | -$3K | -1 | Closed |
|
58
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | – | – |
|
IMUX Hedge Fund Activity: Q3 2016 in Review
51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2016, worth a combined $51.5M — down 5.5% from $54.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IMUX and 5 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Fidelity Investments, cutting an estimated $3.45M.
- 51 institutional investors held Immunic (IMUX) as of Q3 2016, down from 54 in Q2 2016.
- Funds reported $51.5M of Immunic stock for Q3 2016, down 5.5% quarter-over-quarter.
- 5 funds opened new Immunic positions in Q3 2016 and 6 closed out, a net change of -1 holder.
- The largest Immunic buyer in Q3 2016 was Victory Capital Management, an estimated $14.3M added.
- The largest Immunic seller in Q3 2016 was Fidelity Investments, an estimated $3.45M sold.
Based on aggregated 13F filings for Q3 2016.